Atara Biotherapeutics (ATRA) stock forecast for 2026
Last update: 08-15-2022, 12:38Sector: Healthcare
The share price of Atara Biotherapeutics, Inc. (ATRA) now
What analysts predict:: $21.9
52-week high/low: $20.04 / $2.83
50/200 Day Moving Average: $5.3 / $10.61
This figure corresponds to the average price over the previous 50/200 days. For Atara Biotherapeutics stocks, the 50-day moving average is the resistance level today.
For Atara Biotherapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Atara Biotherapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Atara Biotherapeutics stock price in 2026. How much will one Atara Biotherapeutics share be worth in 2026?
Is it worth taking profit / loss on Atara Biotherapeutics stock now or waiting? What are analysts' forecasts for Atara Biotherapeutics stock?
We forecast Atara Biotherapeutics stock performance using neural networks based on historical data on Atara Biotherapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Atara Biotherapeutics stock prediction results are shown below and presented as a graph, table and text information.
Atara Biotherapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Atara Biotherapeutics analysts is $21.9.
Today 200 Day Moving Average is the resistance level (10.61 $).
50 Day Moving Average is the resistance level (5.3 $).
Historical and forecast chart of Atara Biotherapeutics stock
The chart below shows the historical price of Atara Biotherapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Atara Biotherapeutics stock price can be found in the table below.
Atara Biotherapeutics (ATRA) Forecast for 2026
Atara Biotherapeutics information and performance
Atara Biotherapeutic, Inc., a turnkey T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. He is developing tabelecleucel, a T-cell immunotherapy phase III clinical trial for the treatment of rituximab-refractory Epstein-Barr virus (EBV) associated with post-transplant lymphoproliferative disorder, as well as other EBV-related hematological and solid tumors, including carcinoma of the nasopharynx. The company is also developing next-generation CAR T immunotherapy for patients with hematologic malignancies and solid tumors, as well as viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 For B-cell lymphomas, and ATA188, which are in phase I clinical trials for the treatment of multiple sclerosis. He also develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms tumor 1; and ATA621 for BK and JCV. The company has a licensing agreement with the Sloan Kettering Memorial Cancer Center; a license agreement for cooperation in research and development with the Kimr Berghofer Medical Research Institute; and strategic cooperation with the H. Lee Moffitt Cancer Center. Atara Biotherapeutic, Inc. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics Address
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US
Market Capitalization: 551 076 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -290 643 008 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 12.33
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 2.782
Enterprise Value (EV) /Revenue
EV To EBITDA: -0.687
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 94362000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Atara Biotherapeutics price target for 2021 by month
Target values for the price of one Atara Biotherapeutics share for Jan 2026.
Pessimistic target level: 7.77
Optimistic target level: 8.63
Target values for the price of one Atara Biotherapeutics share for Feb 2026.
Pessimistic target level: 8.08
Optimistic target level: 9.15
Target values for the price of one Atara Biotherapeutics share for Mar 2026.
Pessimistic target level: 7.56
Optimistic target level: 8.37
Target values for the price of one Atara Biotherapeutics share for Apr 2026.
Pessimistic target level: 7.97
Optimistic target level: 9.04
Target values for the price of one Atara Biotherapeutics share for May 2026.
Pessimistic target level: 8.87
Optimistic target level: 9.52
Target values for the price of one Atara Biotherapeutics share for Jun 2026.
Pessimistic target level: 8.98
Optimistic target level: 10.07
Target values for the price of one Atara Biotherapeutics share for Jul 2026.
Pessimistic target level: 8.99
Optimistic target level: 10.82
Target values for the price of one Atara Biotherapeutics share for Aug 2026.
Pessimistic target level: 9.43
Optimistic target level: 10.98
Target values for the price of one Atara Biotherapeutics share for Sep 2026.
Pessimistic target level: 9.47
Optimistic target level: 10.35
Target values for the price of one Atara Biotherapeutics share for Oct 2026.
Pessimistic target level: 9.89
Optimistic target level: 10.85
Target values for the price of one Atara Biotherapeutics share for Nov 2026.
Pessimistic target level: 10.56
Optimistic target level: 11.89
Target values for the price of one Atara Biotherapeutics share for Dec 2026.
Pessimistic target level: 10.98
Optimistic target level: 11.95
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.